By Mackenzie Tatananni
Shares of Insmed surged by double digits after the global biopharmaceutical company unveiled positive results for an experimental drug trial.
Shares soared 26% to $89.32 in early trading, putting them on track for their highest close since June 29, 2001, according to Dow Jones Market Data. The S&P 500 and Nasdaq Composite were each up about 0.1%.
Insmed is working on a treatment called treprostinil palmitil inhalation powder taken once daily by patients with pulmonary arterial hypertension, a progressive disease affecting the lungs and heart.
In the latest Phase 2b study, patients saw a statistically significant 35% reduction relative to a placebo in pulmonary vascular resistance, or the amount of pushback blood encounters as it travels through the lungs to the heart.
The biopharma company pledged to immediately engage with the U.S. Food and Drug Administration regarding the design for future studies.
Insmed said it intends to launch a Phase 3 trial for patients with pulmonary hypertension associated with interstitial lung disease before the end of 2025. It plans a Phase 3 trial for patients with PAH in early 2026.
Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
June 10, 2025 09:52 ET (13:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.